[{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"893db886-c712-4cce-b597-bb3b00601a44","acronym":"DISCOVARY","url":"https://clinicaltrials.gov/study/NCT05694819","created_at":"2023-01-23T14:59:43.274Z","updated_at":"2025-02-25T17:25:58.308Z","phase":"Phase 2","brief_title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","source_id_and_acronym":"NCT05694819 - DISCOVARY","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-21"},{"id":"e2eaeeff-423b-47e0-ae9e-fabb69967767","acronym":"NRG-GY033","url":"https://clinicaltrials.gov/study/NCT06169124","created_at":"2023-12-13T21:16:59.860Z","updated_at":"2024-07-02T16:34:27.588Z","phase":"Phase 2","brief_title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","source_id_and_acronym":"NCT06169124 - NRG-GY033","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-10"},{"id":"1a88a82a-3303-489f-8916-22ffac696e62","acronym":"CURATE","url":"https://clinicaltrials.gov/study/NCT05272709","created_at":"2022-03-09T12:52:43.513Z","updated_at":"2024-07-02T16:35:04.084Z","phase":"Phase 1/2","brief_title":"TT-702 in Patients With Advanced Solid Tumours.","source_id_and_acronym":"NCT05272709 - CURATE","lead_sponsor":"Cancer Research UK","biomarkers":" HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • TT-702"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-13"},{"id":"f3fa543f-eaf5-4acd-a3d9-1a89668bc625","acronym":"","url":"https://clinicaltrials.gov/study/NCT03568656","created_at":"2021-01-18T17:33:48.014Z","updated_at":"2024-07-02T16:35:22.821Z","phase":"Phase 1/2","brief_title":"Study to Evaluate CCS1477 in Advanced Tumours","source_id_and_acronym":"NCT03568656","lead_sponsor":"CellCentric Ltd.","biomarkers":" MYC • AR • ARID1A • CREBBP","pipe":" | ","alterations":" ARID1A mutation • CREBBP mutation • EP300 mutation","tags":["MYC • AR • ARID1A • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • CREBBP mutation • EP300 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab) • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • inobrodib (CCS1477)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/23/2018","start_date":" 07/23/2018","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-01-19"},{"id":"7a4df5f8-d679-43c6-a55a-2239edf5514e","acronym":"UCBG3-06 START","url":"https://clinicaltrials.gov/study/NCT03383679","created_at":"2021-01-18T16:41:49.948Z","updated_at":"2024-07-02T16:36:00.149Z","phase":"Phase 2","brief_title":"Study on Androgen Receptor and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03383679 - UCBG3-06 START","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Nubeqa (darolutamide)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 03/14/2018","start_date":" 03/14/2018","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-11-21"},{"id":"2617e1c4-8e40-4f47-ad02-deaaff413d77","acronym":"TRIO030","url":"https://clinicaltrials.gov/study/NCT03004534","created_at":"2021-01-18T14:46:46.920Z","updated_at":"2025-02-25T17:23:24.254Z","phase":"Phase 1","brief_title":"A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide","source_id_and_acronym":"NCT03004534 - TRIO030","lead_sponsor":"Translational Research in Oncology","biomarkers":" HER-2 • AR","pipe":"","alterations":" ","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 02/14/2019","primary_completion_date":" 02/14/2019","study_txt":" Completion: 03/13/2019","study_completion_date":" 03/13/2019","last_update_posted":"2020-04-03"},{"id":"f96605e3-4554-4991-a4d4-84472b69a2ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01317641","created_at":"2023-10-15T04:12:49.115Z","updated_at":"2024-07-02T16:37:24.016Z","phase":"Phase 2","brief_title":"Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT01317641","lead_sponsor":"Orion Corporation, Orion Pharma","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2017-03-29"}]